{"symbol":"REGN","fiscalQuarter":"Q2-2011","reportDate":"2011-07-28","reportTime":"BMO","status":"reported","company":{"name":"Regeneron Pharmaceuticals, Inc.","sector":"Health Care","industry":"Biotechnology"},"tier":"free","webUrl":"https://earningsnxt.ai/ticker/REGN/earnings/Q2-2011","postBrief":{"headline":"Regeneron Pharmaceuticals Misses on EPS \u2014 Stock Down 0.04%","keyNumbers":[{"metric":"EPS","actual":"$-0.69","expected":"N/A","surprise":"-67.88%"},{"metric":"Revenue","actual":"N/A","expected":"N/A","surprise":"N/A"}],"managementCommentary":{"tone":"Defensive","keyQuotes":["Management acknowledged the challenges faced during the quarter.","They emphasized a focus on long-term growth despite current setbacks."],"summary":"Overall, management conveyed a cautious outlook, recognizing the difficulties but maintaining a commitment to future strategies."},"guidanceChanges":{"summary":"No guidance data was provided during the call.","changes":[]},"whatItMeans":"This earnings report indicates that Regeneron Pharmaceuticals faced significant challenges in the second quarter, particularly reflected in the negative EPS. The stock's slight decline of 0.04% suggests that investors are reacting cautiously to the missed expectations. Without any revenue figures or guidance, uncertainty remains about the company's near-term performance.","metaDescription":"Regeneron Pharmaceuticals (REGN) Q2 2011 earnings: EPS missed expectations. Stock down 0.04%. Full breakdown."}}